Prof. Dr. Erdal Karaöz
Prof. Dr. Erdal Karaöz, histoloji ve embriyoloji profesörü olup Türkiye'nin en çok atıf alan kök hücre bilim insanlarından biridir. Kendisi, StemCell Longevita tarafından koordine edilen mezenkimal kök hücre ve eksozom programlarının bilimsel yönünü yönetmekte ve bu sitedeki klinik içeriğin tıbbi incelemecisi olarak görev yapmaktadır.
Kimlik ve nitelikler
| Alan | Detay |
|---|---|
| Tam ad | Prof. Dr. Erdal Karaöz (Erdal Karaoz) |
| Birincil uzmanlık | Histoloji ve embriyoloji; rejeneratif tıp ve kök hücre biyolojisi |
| Tıp fakültesi | Dicle Üniversitesi Tıp Fakültesi, 1986 |
| Doktora | Histoloji ve Embriyoloji, Gazi Üniversitesi, 1994 |
| Profesörlük | Histoloji ve Embriyoloji Profesörü |
| Araştırma bursu | Misafir araştırmacı, Joslin Diyabet Merkezi, Harvard Tıp Fakültesi, Boston (2005) |
| Kurucu rolü | Kocaeli Üniversitesi Kök Hücre ve Gen Tedavileri Araştırma ve Uygulama Merkezi (SCGTR) kurucusu, 2006 |
| Diller | Türkçe, İngilizce |
Kurumsal bağlantılar
Prof. Karaöz'ün klinik ve laboratuvar çalışmaları üç bağlantılı kurumda yürütülmektedir: tedavi hastanesi, üniversite fakültesi ve GMP hücre üretim laboratuvarı.
- Liv Hospital Ulus, İstanbul — Rejeneratif Tıp ve Kök Hücre Araştırma ve Tedavi Merkezi Başkanı ve koordine edilen prosedürlerin gerçekleştirildiği yer.
- İstinye Üniversitesi Tıp Fakültesi, İstanbul — profesör ve araştırmacı.
- ONKIM Kök Hücre Teknolojileri GMP laboratuvarı — hücre işleme, karakterizasyon ve serbest bırakma testlerinin bilimsel liderliği.
- StemCell Longevita — Koordineli tedavi programları için Tıbbi Direktör ve Baş Kök Hücre Bilimcisi.
Araştırma tanımlayıcıları ve bağımsız kayıtlar
Bu sayfadaki her iddia üçüncü taraf veri tabanları üzerinden kontrol edilebilir. Yalnızca aktif olarak sürdürülen profillere bağlantı veriyoruz; bir tanımlayıcının herkese açık olarak yayınlanmadığı durumlarda, uydurmak yerine bunu belirtiyoruz.
| Kayıt | Bağlantı | Durum |
|---|---|---|
| Google Scholar | scholar.google.com profili | Sürdürülüyor — 190'dan fazla indekslenmiş yayın |
| PubMed | PubMed yazar araması: Karaoz E | Bağımsız NIH indeksi |
| ResearchGate | researchgate.net/profile/Erdal-Karaoz | Profesyonelce sürdürülüyor |
| linkedin.com/in/erdalkaraoz | Profesyonelce sürdürülüyor | |
| Hastane profili | Liv Hospital doktor profili | İşveren tarafından yayınlanmış |
| ORCID | Yazım anında herkese açık olarak yayınlanmamış | Kayıt olduktan ve kamuya açıldıktan sonra iD'yi buraya listeleyeceğiz |
Seçilmiş hakemli yayınlar
Aşağıdakiler, bu sitede açıklanan protokollerin temelini oluşturan mezenkimal kök hücre, Wharton jeli, omurilik yaralanması ve immünomodülasyon çalışmalarının temsilcileridir. Tam liste Google Scholaradresindedir.
- Kemik iliği, Wharton jeli ve adipoz doku kaynaklı insan mezenkimal kök hücrelerinin immünosüpresif özelliklerinin karşılaştırmalı analizleri — Turkish Journal of Haematology, 2017
- İnsan dental pulp kök hücreleri, kemik iliği kaynaklı mezenkimal kök hücrelerden daha iyi nöral ve epitelyal kök hücre özellikleri sergiler — Histochemistry and Cell Biology, 2011
- Sıçan kemik iliğinden mezenkimal kök hücrelerin karakterizasyonu: ultrastrüktürel özellikler, farklılaşma potansiyeli ve immünofenotipik belirteçler — Histochemistry and Cell Biology, 2009
- Sıçan kemik iliği kaynaklı mezenkimal kök hücrelerle ortak kültürleme yoluyla sıçan pankreatik adacık fonksiyonunun ve canlılığının korunması — Cell Death & Disease, 2010
- The systematic effect of mesenchymal stem cell therapy in critical COVID-19 patients: a prospective double controlled trial — Cell Transplantation, 2021
- Reduction of lesion in injured rat spinal cord and partial functional recovery of motility after bone marrow derived mesenchymal stem cell transplantation — Turkish Neurosurgery, 2012
- Efficacy of stem cell therapy in ambulatory and nonambulatory children with Duchenne muscular dystrophy — Phase I–II — Degenerative Neurological and Neuromuscular Disease, 2018
- Olfactory ensheathing cells: unique glial cells promising for treatments of spinal cord injury — Journal of Neuroscience Research, 2021
Role in treatment planning
Prof. Karaöz's role is scientific and supervisory rather than administrative. In practice this means:
- Defining the cell source, dose range and delivery route used for each indication — for example Wharton's jelly MSCs for autoimmune and neurological programmes.
- Setting the laboratory release criteria (viability, sterility, endotoxin, phenotype) that a batch must meet before it can be released for a patient.
- Reviewing candidacy on complex cases where imaging, disease stage or previous therapy affect whether treatment is appropriate at all.
- Signing off the protocol documents behind the treatment pages and the evidence summaries.
Medical review role
Prof. Karaöz is the named medical reviewer for the clinical pages of this site. Reviewed pages carry a "Medically reviewed by Prof. Dr. Erdal Karaöz Ekibi" byline linking back to this profile, with the review date shown. Our review process, correction policy and sourcing rules are documented in the editorial standards.
Pages that are administrative rather than clinical — pricing logistics, travel information, policies — are not medically reviewed and do not carry the byline.
Institutional affiliations
Each affiliation below is listed with the role held and the period it covers, so a reader can check the claim against the institution rather than against this page.
| Institution | Role | Period | Verify |
|---|---|---|---|
| Liv Hospital Ulus, Istanbul | Medical Director, Center for Regenerative Medicine and Stem Cell Therapy | 2016 – present | Verify |
| Istinye University, Istanbul | Professor of Histology and Embryology; Director, Center for Stem Cell and Tissue Engineering Research (ISUKOK) | 2016 – present | Verify |
| ONKIM Stem Cell Technologies | Founder and scientific lead, GMP cell manufacturing | 2014 – present | Verify |
| Kocaeli University, Faculty of Medicine | Professor of Histology and Embryology; founding director of the Stem Cell and Gene Therapies Research and Application Centre | 2004 – 2016 | Verify |
Publication record
Every title links to a PubMed title search rather than to a copy hosted here, so you always see the current record, including any correction or retraction notice. The complete list is on Google Scholar and ResearchGate.
Turkish Journal of Haematology, 2017 — Underpins why Wharton's jelly is the default cell source described on this site.
Cell Transplantation, 2021 — Controlled human data on systemic MSC infusion and safety monitoring.
Degenerative Neurological and Neuromuscular Disease, 2018 — Early-phase human evidence referenced on our neuromuscular pages.
Histochemistry and Cell Biology, 2011 — Cell-source characterisation work behind our laboratory identity panels.
Histochemistry and Cell Biology, 2009 — Preclinical characterisation; cited as laboratory, not clinical, evidence.
Cell Death & Disease, 2010 — Mechanistic (animal) evidence referenced on metabolic pages.
Turkish Neurosurgery, 2012 — Preclinical basis for the spinal cord injury discussion pages.
Olfactory ensheathing cells: unique glial cells promising for treatments of spinal cord injury
Journal of Neuroscience Research, 2021 — Review of neural repair strategies beyond MSCs.
How these papers are weighted when we write clinical pages is set out in How we evaluate evidence.
Conferences and scientific meetings
Prof. Karaöz presents and teaches regularly in the following scientific settings. We list the societies and the subject matter rather than a promotional talk count; a dated presentation list with slides can be requested for due-diligence purposes.
International Society for Cell & Gene Therapy (ISCT)
Cell-source comparison and potency assays for clinical-grade MSC products
Turkish Society for Stem Cell and Cellular Therapies / national congresses
GMP manufacturing, release criteria and regulatory framework in Türkiye
TERMIS (Tissue Engineering and Regenerative Medicine International Society)
Wharton's jelly MSC characterisation and tissue-engineering applications
University and hospital scientific meetings (Istinye University, Liv Hospital)
Clinical governance of cell therapy: candidacy, dosing and follow-up
Expert video explanations
Recorded explanations are published here as they are produced, each with a written summary so the content is readable without playing the video.
Inside the GMP laboratory and treatment pathway
Summary of what is explained in this video: Walkthrough of the laboratory and clinical pathway described on this profile: how a Wharton's jelly cell line is characterised, which release tests a batch must pass before it can be used, and where the medical reviewer sits in that chain.
Frequently asked questions
Is Prof. Dr. Erdal Karaöz a medical doctor?
Yes. He graduated in medicine from Dicle University in 1986 and went on to complete a PhD and professorship in histology and embryology, the discipline underpinning cell therapy.
Does Prof. Karaöz personally perform every procedure?
No. He leads the scientific and laboratory side and reviews protocols and complex candidacy decisions. Procedures are performed by the treating clinical team at Liv Hospital Ulus.
How can I independently verify his publications?
Search "Karaoz E" on PubMed, which is maintained by the US National Library of Medicine and is not controlled by this clinic.
Ask for the documentation
Our coordination team can share laboratory certificates, licence references and hospital accreditation details during your consultation, alongside a medical review of your own records.
Ücretsiz tıbbi değerlendirme talebinde bulunun